Eli Lilly reports retatrutide results for Eli Lilly and Company stock

Published on 10/28/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Retatrutide cut A1C to 2.2 percent versus 1.8 percent. Eli Lilly and Company stock costs EUR 1,158.90 on October 28, 2026, versus EUR 1,149.00.

Retatrutide sets a stronger efficacy benchmark

Eli Lilly reported that retatrutide lowered A1C by 2.2 percent versus 1.8 percent with Ozempic at 80 weeks.
Weight loss reached 20.9 percent with the 12 mg dose versus 9.4 percent with Ozempic.
Discontinuation due to adverse events was 7.9 percent with 12 mg retatrutide versus 2.7 percent with Ozempic.
The stock traded at EUR 1,158.90 on October 28, 2026, plus 0.86 percent versus the EUR 1,149.00 Xetra close.

Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Eli Lilly and Company (ISIN US5324571083) reported on October 28, 2026, that its investigational retatrutide lowered A1C by 2.2 percent at 80 weeks, compared with 1.8 percent for Ozempic 2 mg. The result gives Lilly a stronger efficacy comparison for its next-generation cardiometabolic program, while the safety profile remains an important counterweight.

Retatrutide beats the active comparator

In the TRANSCEND-T2D-2 Phase 3 trial, the 12 mg retatrutide dose produced average weight loss of 20.9 percent, or 47.4 pounds, versus 9.4 percent, or 20.9 pounds, with Ozempic 2 mg. The 9 mg dose produced weight loss of 19.5 percent, or 44.3 pounds. The trial included 1,298 adults with type 2 diabetes.

According to the Eli Lilly and Company release dated October 28, 2026, retatrutide also improved non-HDL cholesterol, triglycerides and systolic blood pressure compared with Ozempic. Detailed results are scheduled for presentation at a future medical meeting and publication in a peer-reviewed journal.

Tolerability is the key counterweight

The efficacy advantage came with higher treatment discontinuation due to adverse events at the 12 mg dose. The rate was 7.9 percent for 12 mg retatrutide, versus 2.7 percent for Ozempic, while the 9 mg rate was 4.8 percent. Diarrhea occurred in 32.7 percent of patients on 12 mg retatrutide and 26.4 percent on Ozempic.

Retatrutide remains investigational and has not been approved by the FDA or another regulatory authority. Lilly is due to announce third-quarter 2026 results on October 29, 2026, with the conference call scheduled for 10:00 a.m. Eastern time, according to its October 15 release.

Stock trades above the Xetra close

At Lang & Schwarz, Eli Lilly and Company stock was trading at EUR 1,158.90 on October 28, 2026, at 5:10 p.m. CET, plus 0.86 percent versus the Xetra close of October 27, 2026, at EUR 1,149.00. The market is now weighing retatrutide's efficacy advantage against its higher discontinuation rate before Lilly's quarterly update.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co stock.